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n order for the nervous system to 
function properly, precise connec-
tions must be formed between indi-
vidual neurons and the cells they synapse 
with. The growing ends of axons often 
travel long distances, integrating both 
attractive and repulsive cues along the 
way, before reaching their destinations. 
Rüdiger Klein has spent much of his ca-
reer deciphering the guideposts axons use 
during their treks (1–4).
Klein’s career didn’t follow a straight 
path, though, as he traveled through 
several different countries and research 
subjects early in his career. He visited 
South America and spent time in the 
United States as both an undergraduate 
exchange student and as a postdoc (5). 
But ultimately he returned to his native 
Germany, where he is now Director of 
Molecular Neuroscience at the Max Planck 
Institute of Neurobiology in Martinsried. 
We reached him there to talk about his 
intellectual and physical travels.
WANDERLUST
How did you decide on a career in 
research?
My biology teacher in high school was 
very infl  uential. The way he taught us 
was very exciting, and I got excited about 
ecology. I enrolled in biology at univer-
sity because of him.
At fi  rst, I wanted to be-
come a political biologist, 
like one of those people 
who are in the Green Party, 
saving the environment. 
However, my father (who 
was in politics; he was the 
opposition leader in the 
German state of Rheinland-
Pfalz, and the mayor of the town where 
I grew up) pointed out that there are 
very few jobs in that profession. I de-
cided I wanted to become a parasitolo-
gist instead because I was excited about 
the complicated life cycles that para-
sites go through, and I also thought that by 
studying parasitology I could help people. 
But then, before starting my PhD, I took 
a trip to South America and visited some 
hospitals while I was there. It was de-
pressing. The working conditions were 
poor, and it was very hard to get money 
for research, so I decided to change my 
focus again. I studied virally encoded 
platelet-derived growth factor during 
my PhD.
And then you did your postdoc with 
Mariano Barbacid?
Yes. Mariano, who was at the National 
Cancer Institute in Frederick, Maryland, 
when I joined his lab, had just cloned an 
oncogene that he called Trk. It looked 
like a receptor, but they had no idea 
what it did or what its ligand was. So, 
my fi   rst job was to clone the mouse 
homologue of this human oncogene so 
that we could study its expression dur-
ing mouse development and maybe fi  nd 
out its normal function. I started screen-
ing a mouse brain cDNA library with a 
human Trk probe, pulled out some clones 
and sequenced them. They looked simi-
lar to Trk, but they were not identical, 
so we knew we had a different gene; we 
called it TrkB, and started calling the 
original gene TrkA. But I wasn’t able to 
pull out mouse TrkA—I only pulled out 
this new gene.
On the one hand, Mari-
ano was happy that we had 
found this new gene, but on 
the other he was still unsat-
isfi  ed because he wanted to 
have the original one. So 
another postdoc, Fabienne 
Lamballe, and I went back 
and this time screened the 
library with both the human 
TrkA probe and the mouse TrkB probe 
to try to pull out mouse TrkA. Instead, 
we found a third Trk gene and called it 
TrkC [laughs].
In fact, we never pulled out mouse 
TrkA from this brain library. Later, we 
found out why: there is very little TrkA 
in the brain. TrkB and TrkC are mostly 
found in the brain, but TrkA is mostly 
found in the peripheral nervous system, 
in sensory neurons and so forth, where 
it is a receptor for NGF, which supports 
these neurons. So then we went on to 
use knockout technology to disrupt these 
genes in mice. It was exciting to see that 
when you knock out the TrkA gene all 
the neurons that express it—ones that 
innervate the skin and are responsible 
for sensation of heat and pain—die, so 
the mice basically have no sense of heat 
or pain.
DECISIVE MOVE
You continued to study Trk in your own 
lab at EMBL in Germany?
For a little while, yes, but then I decided 
to move into a slightly different family 
of receptor tyrosine kinases. As a post-
doc, I had been fortunate to learn how to 
make knockout mice—that was a new 
technology at the time, and it wasn’t 
available in many places—and I wanted 
to use knockout technology to study or-
phan receptors.
I was intrigued by the interesting ex-
pression patterns of some novel orphan 
receptors called Eph receptors (or Ephs), 
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Klein uses genetically modified mice to study how axons find the right targets to innervate.
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“It looked like 
a receptor, 
but they had 
no idea what 
it did.”
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so we started making knockouts of the 
receptors. Right around this time, the li-
gands of these Ephs were found. It be-
came clear that one of these ligands, 
which are now called ephrins, is an axon 
guidance cue. So then we knew what to 
look for in the mice, and it only took a few 
weeks to fi  nd that some of the major axon 
bundles in the brain were misguided in 
our Eph knockout mice.
One interesting thing that we’ve dis-
covered since we started working on 
ephrin and Eph signaling is that it is bi-
directional. For example, one group of 
ephrins, the B-type ephrins, look like 
little receptors; they have a transmem-
brane domain and an intracellular por-
tion. Both we and Tony Pawson’s lab in 
Toronto, with whom we were collaborating, 
independently found that B-type ephrins 
are transiently phosphorylated on an 
intra cellular tyrosine residue when they 
bind to an Eph receptor. That was a very 
clear indication that the B-type ephrins 
could do reverse signaling, and now peo-
ple have also found that the A-type ephrins 
(which do not have an intracellular do-
main) can as well, by interacting with 
other transmembrane proteins that serve 
as coreceptors.
What purpose do Eph receptor signaling 
and ephrin reverse signaling serve?
You can fi   nd situations in which one 
cell is purely giving a signal but does 
not respond to a signal; it’s like a guide-
post cell. Let’s take the example of the 
spinal cord midline, which expresses a 
B-type ephrin: it makes sure that axons 
that are not supposed to 
cross the midline stay on 
one side and find their 
synaptic partners on that 
side. If you remove the 
ephrin or its correspond-
ing Eph genetically, those 
axons cross the midline 
and cause trouble. But, if 
you just truncate the B-
type ephrin so that it can-
not signal into the midline 
cells, then you have no phenotype. Those 
midline cells present the ephrin, but they 
don’t respond to an axon that binds to 
them. There are many situations like 
this where signaling is only required 
unidirectionally; it can occur either 
from the ephrins to the Ephs or the other 
way around.
On the other hand, Ephs and ephrins 
are also involved in the development of 
blood vessels. Here, it is believed that 
when a blood vessel wants to grow a 
new sprout both Ephs and ephrins need 
to become activated so that cells can 
lose contact, move away from one an-
other, and start dividing to form a new 
sprout. The signaling is really bidirec-
tional in this situation.
CURRENT DIRECTION
In what direction are you now headed 
with this work?
One of the questions we’re interested in is 
how Ephs and ephrins mediate contact re-
pulsion. The fi  rst thing that happens is 
ephrins binding to Ephs, which are high-
affi   nity binding interactions. Normally 
such interactions mediate adhesion, but in 
this case they do the opposite.
What we’ve found is that you have to 
destroy or remove this ligand-receptor 
complex from the cells’ surface for the 
cells to detach. There are two ways this 
can happen: either through activating 
metalloproteases that cleave the ecto-
domains or by another rather aggressive 
method where cells actually eat a piece 
from the opposing cell and engulf—
phagocytose—the entire Eph-ephrin com-
plex. We would really like to understand 
that pathway.
Another question that 
interests me is that, under 
certain conditions, Eph-
ephrin signaling is attrac-
tive instead of repulsive. 
For example, when a neu-
ron’s axon arrives at its 
fi  nal target, Ephs and eph-
rins help to make synapses. 
How cells switch between 
repulsion and attraction is 
not understood. And, we’re 
examining how neuro  trophic factors—
which are often attractive for axons—
might act as a counterpart to ephrins. We 
want to understand how axons integrate 
attractive and repulsive cues.
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A motor axon growth cone (green) 
approaching a cell expressing an ephrin (red).
“We want 
to understand 
how axons 
integrate 
attractive 
and repulsive 
cues.”
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Section of a mouse transgenic embryo with 
motor (red + green) and sensory (red) neurons 
highlighted. Islet1 is shown in blue.